share_log

Aslan Pharmaceuticals Reports Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-Experienced Atopic Dermatitis Patients

Aslan Pharmaceuticals Reports Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-Experienced Atopic Dermatitis Patients

阿斯蘭製藥報告了Eblasakimab在經歷過Dupilumab的特應性皮炎患者中進行Eblasakimab的2期研究的中期結果
Moomoo 24/7 ·  04/22 08:33
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論